Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, under
Target Price
The average target price of GMAB.CO is 2072 and suggests 2% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell